Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Stock Information for Cybin Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cybin Inc.

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones 
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cybin Announces Closing of the Oversubscribed Private Placement of U.S. $150 Million
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.